Product Description
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Austria | Bangladesh | European Medicines Agency | Hong Kong | India | Malaysia | Norway | Pakistan | Poland
Approved Indications: None
Known Adverse Events: None
Company: Dr Taufiq Binjemain
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ACTRN12623001164684 | N/A |
Not yet recruiting |
Nose Cancer |
2025-06-30 |